Table 1.

Relationship among NE levels, genotype, and survival in patients treated with bucindolol

NE group	Mortality HR, Arg:Gly	95% C.I.	Cox P value	No. of events
BSL NE (n)
64–356 (146)	0.90	0.37, 2.22	0.82	19
358–545 (144)	0.74	0.37, 1.51	0.41	31
546–2571 (149)	0.68	0.32, 1.47	0.33	29
Change in NE* (n)
Group 1 (70)	1.07	0.41, 2.78	0.89	17
Group 2 (248)	0.82	0.43, 1.59	0.56	36
Group 3 (54)	0.36	0.11, 1.15	0.08	14

The cutpoints for NE change in the three groups were determined from a previously published likelihood analysis (22) from BEST. These were (i) those with a >244 pg/ml reduction in NE with treatment that was associated with a 1.69-fold increased mortality, (ii) a reference group with little or no change in NE (−244 to +145 pg/ml) not found to be at risk for increased mortality, and (iii) those with a >145 pg/ml increase in NE with treatment associated with a 1.65-fold increased mortality. BSL, baseline.

*Change in NE from baseline after 3 months of bucindolol treatment.